Patients with severe asthma reducing ICS treatment during treatment with biologicals do not have more frequent exacerbations.

Advances in the management of asthma and allergic airways disease

Chair(s): Christian Taube, Christina Bal

Session type: Poster session

Torben Smidt-Hansen

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Response to biologics and clinical remission in the adult GAN severe asthma cohort.

Katrin Milger-kneidinger

Poster

Abstract

Mepolizumab long-term safety in severe eosinophilic asthma

Ian Douglas Pavord

Poster

Abstract

Late Breaking Abstract - Comparability and usability of FeNO analyzers: a LEAD prospective general population study

Christina Bal

Poster

Abstract

Role of atopy in occupational asthma

Amira Belkahla

Abstract

Anti-IgE Ab treatment attenuates OVA-Ag-induced neutrophilic airway inflammation and IL-17 production in the lungs

Kazuyuki Nakagome

Poster

Abstract

Assessement of the Healthcare Providers Knowledge, Practice and Attitudes Towards Allergen-Specific Immunotherapy

Asma Saidane

Poster

Abstract

Results of health education training for asthmatic patients: A prospective cohort study

Bandi Solongo

Abstract

Dupilumab may be beneficial for severe asthma patients with high FeNO And low blood eosinophil counts in real world observational study.

Tatsuhiko Uno

Poster

Abstract

Factors predictive of poor adherence to treatment in patients with asthma

Aboubekr Imzil

Abstract

Real-world mepolizumab outcomes in severe asthma: REALITI-A post hoc analysis by exacerbation history

Diego Bagnasco

Poster

Abstract

Patients with severe asthma reducing ICS treatment during treatment with biologicals do not have more frequent exacerbations.

Torben Smidt-hansen

Poster

Abstract

Impact of smoking on biologicals treatment response in patients from the German Severe Asthma (GAN) Registry

Slagjana Stoshikj

Poster

Abstract

Therapeutic effect and mechanism study of 35 kDa Progesterone-induced blocking factor for elderly female asthmatic patients

Hyun Jae Shim

Poster

Abstract

German Asthma Net: Characterization of responders of anti-IL5 and anti-IL5(R) therapy

Christina Bal

Poster

Abstract

Impact of staphylococcus aureus enterotoxins on clinical responses to omalizumab in severe asthma patients

Wei-ciao Wu

Poster

Abstract

A modified COMSA score is a good tool to identify responders and non-responders to mepolizumab in severe asthma

Valentyna Yasinska

Poster

Abstract

Impact of inhaled corticosteroids on specific inhalation challenges for diagnosing occupational asthma

Gabriel Lavoie

Poster

Abstract

A real-life comparison of patients with severe eosinophilic asthma treated with benralizumab or mepolizumab

Helle Haagensen Andersen

Poster

Abstract

Late Breaking Abstract - Clinical remission with mepolizumab in severe asthma: impact of lung function parameters

John Oppenheimer

Poster

Abstract

The ERS International Congress 2023, Milan

#{title}